<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390113</url>
  </required_header>
  <id_info>
    <org_study_id>AVM-003-HC</org_study_id>
    <nct_id>NCT04390113</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)</brief_title>
  <official_title>Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlloVir</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlloVir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate ALVR105 (Viralym-M); an allogeneic, off-the-shelf multi-virus specific T&#xD;
      cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus,&#xD;
      Epstein-Barr virus, human herpesvirus 6 and JC virus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study hypothesis is that the administration of ALVR105 to patients with virus-associated&#xD;
      HC will demonstrate superiority for the time to resolution of HC (as measured by resolution&#xD;
      of macroscopic hematuria) compared to patients treated with placebo. The primary hypothesis&#xD;
      will be tested in patients with BK virus (BKV) viruria to demonstrate superiority over&#xD;
      placebo in this population (BK Intent-to-Treat [ITT] Population). A supplementary analysis&#xD;
      will be conducted in all patients with any virus-associated HC (cytomegalovirus [CMV], human&#xD;
      herpesvirus 6 [HHV-6], Epstein-Barr virus [EBV], JC virus [JCV], and/or adenovirus [AdV]) in&#xD;
      order to evaluate efficacy in this broader population (ITT Population).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 18, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time until urine is visually clear of hematuria</measure>
    <time_frame>Until event occurrence through week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time until bladder pain is resolved</measure>
    <time_frame>Until event occurrence through week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in the hospital for any reason</measure>
    <time_frame>Until event occurrence through week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to resolution for target all viruses</measure>
    <time_frame>Until event occurrence through week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average daily bladder/lower abdominal pain</measure>
    <time_frame>Until event occurrence through week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute graft versus host disease and cytokine release syndrome</measure>
    <time_frame>Until event occurance through week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>BK Virus Infection</condition>
  <condition>Hemorrhagic Cystitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered as 2-4 milliliter infusion, visually identical to ALVR105 (Viralym-M)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALVR105 (Viralym-M)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered as 2-4 milliliter infusion, visually identical to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALVR105 (Viralym-M)</intervention_name>
    <description>Administered as 2-4 milliliter infusion, visually identical to placebo</description>
    <arm_group_label>ALVR105 (Viralym-M)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as 2-4 milliliter infusion, visually identical to ALVR105 (Viralym-M)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
        Participants must meet all of the following criteria in order to be eligible to participate&#xD;
        in the study:&#xD;
&#xD;
          -  Male or female of any age.&#xD;
&#xD;
          -  Had an allogeneic hematopoietic cell transplant (HCT) performed ≥21 days and ≤1 year&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Myeloid engraftment confirmed, defined as an absolute neutrophil count ≥500/mm³ for 3&#xD;
             consecutive laboratory values obtained on different days, and platelet count&#xD;
             &gt;10,000/mm³ at the time of randomization.&#xD;
&#xD;
          -  Diagnosed with HC based on the following criteria (all 3 criteria must be met):&#xD;
&#xD;
               1. Clinical signs and symptoms of cystitis, including dysuria, lower abdominal pain,&#xD;
                  and/or other bladder-associated pain or spasms.&#xD;
&#xD;
               2. Grade ≥3 hematuria, defined as macroscopic hematuria with visible clots.&#xD;
&#xD;
               3. Viruria of &gt;5 log10 copies/mL of at least 1 target virus (ie, BKV, JCV, AdV, CMV,&#xD;
                  EBV, and/or HHV-6).&#xD;
&#xD;
          -  At least 1 identified, suitably matched ALVR105 cell line for infusion is available.&#xD;
&#xD;
        Key Exclusion Criteria&#xD;
&#xD;
        Participants who meet any of the following criteria will be excluded from participation in&#xD;
        the study:&#xD;
&#xD;
          -  Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone dose &gt;0.5&#xD;
             mg/kg/day or equivalent).&#xD;
&#xD;
          -  Therapy with antithymocyte globulin, alemtuzumab (Campath-1H), or other&#xD;
             immunosuppressive T cell-targeted monoclonal antibodies &lt;28 days before randomization.&#xD;
&#xD;
          -  Evidence of active Grade &gt;2 acute graft versus host disease (GVHD).&#xD;
&#xD;
          -  Uncontrolled or progressive bacterial or fungal infections.&#xD;
&#xD;
          -  Uncontrolled or progressive viral infections not targeted by ALVR105.&#xD;
&#xD;
          -  Uncontrolled or progressive EBV-associated post-transplant lymphoproliferative&#xD;
             disorder.&#xD;
&#xD;
          -  Known or presumed pneumonia secondary to any organism that is not considered to be&#xD;
             well-controlled by antimicrobial therapy.&#xD;
&#xD;
          -  Pregnant or lactating or planning to become pregnant.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyle Herbert</last_name>
    <phone>+1 833-409-2281</phone>
    <email>ClinicalTrials@allovir.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado - Center for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Moffitt</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center (OSUMC)</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon and HCA Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7.</citation>
    <PMID>28783452</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic Hematopoietic Cell Transplant</keyword>
  <keyword>ALVR105</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

